DVA | Ticker Profile - Titan Protect

DVA

DaVita

Health Care · Health Care Services · US

$192.16

Data: 2025-12-31

✗ ETHICAL FAIL

NARROW MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$12.8B

Total market value of the company

Trailing P/E

19.10

Reasonably valued

Forward P/E

11.50

Based on estimated future earnings — lower means cheaper

Rev Growth

+6.0%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

81.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$193.71

+1% from current price — median analyst estimate

Recommendation

HOLD

Consensus view from 7 analysts covering this stock

About DaVita

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

https://www.davita.com

Country: United States Employees: 78,000 Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

73.7% FAIL

Debt must be below 33% of total assets

Cash Ratio

0.2% PASS

Interest-bearing cash below 33% of assets

Receivables

17.7% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$344.00

What our model estimates this business is worth per share

Margin of Safety

44.1%

Trading below fair value — margin of safety exists

Rating

AVOID

Overall assessment combining ethics, valuation, and quality

Percentile

77.0th

Ranks in the top 23% of our 13,571 screened universe

Ethical Score

10.0

Valuation Score

88.0

Quality Score

57.0

Combined

46.5

Trading at $199 against a fair value of $344, a 42% discount. Fails ethical screen (Debt ratio). Ranks better than 78% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.597

Good returns relative to risk taken

Kelly Fraction

0.0544

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.406

Drawdown risk outweighs the returns — higher risk profile

Annual Return

16.8%

Historical annualised return based on price data

Max Drawdown

-41.4%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.84

Less volatile than the market — more defensive

52W High

$202.69

5% below the year high

52W Low

$101.00

90% above the year low

Avg Volume

867,714

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

18.1%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$10.39

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

12.61

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.42

Adequate but worth monitoring

Quick Ratio

1.28

Like current ratio but excludes inventory — stricter test

Gross Margin

32.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

13.9%

Profit from core operations before interest and tax

Free Cash Flow

$1,000M

Positive — the business generates more cash than it spends

Revenue (TTM)

$13.8B

Total revenue over the last 12 months

Net Income

$756M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$235.00

Target Median

$193.71

Target Low

$145.00

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Shares	Value
2026-05-15	SCHECHTER ADAM H	Director	250	—
2026-05-15	YALE PHYLLIS R	Director	250	—
2026-05-15	DESOER BARBARA J	Director	250	—
2026-05-15	ARWAY PAMELA M.	Director	250	—
2026-05-15	PULLIN DENNIS W	Director	250	—
2026-05-15	SCHOPPERT WENDY LEE	Director	250	—
2026-05-15	HOLLAR JASON M	Director	250	—
2026-05-15	MOORE GREGORY J	Director	250	—
2026-05-15	HEARTY JAMES O	Officer	15,000	$2,909,745
2026-05-14	HEARTY JAMES O	Officer	5,784	$639,884

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
5 May2026	Josh Gottheimer	Democrat	buy	1K–15K
27 Apr2026	Josh Gottheimer	Democrat	buy	1K–15K
23 Apr2026	Josh Gottheimer	Democrat	buy	1K–15K
2026-04-27	Josh Gottheimer	Democrat	Purchase	1K–15K
2026-04-24	Ro Khanna	Democrat	Purchase	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2025-12-31

Before you go